1
|
Jackson JL, Kuriyama A, Kuwatsuka Y, Nickoloff S, Storch D, Jackson W, Zhang ZJ, Hayashino Y. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One 2019; 14:e0212785. [PMID: 30893319 PMCID: PMC6426199 DOI: 10.1371/journal.pone.0212785] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Accepted: 02/10/2019] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Headaches are a common source of pain and suffering. The study's purpose was to assess beta-blockers efficacy in preventing migraine and tension-type headache. METHODS Cochrane Register of Controlled Trials; MEDLINE; EMBASE; ISI Web of Science, clinical trial registries, CNKI, Wanfang and CQVIP were searched through 21 August 2018, for randomized trials in which at least one comparison was a beta-blocker for the prevention of migraine or tension-type headache in adults. The primary outcome, headache frequency per month, was extracted in duplicate and pooled using random effects models. DATA SYNTHESIS This study included 108 randomized controlled trials, 50 placebo-controlled and 58 comparative effectiveness trials. Compared to placebo, propranolol reduced episodic migraine headaches by 1.5 headaches/month at 8 weeks (95% CI: -2.3 to -0.65) and was more likely to reduce headaches by 50% (RR: 1.4, 95% CI: 1.1-1.7). Trial Sequential Analysis (TSA) found that these outcomes were unlikely to be due to a Type I error. A network analysis suggested that beta-blocker's benefit for episodic migraines may be a class effect. Trials comparing beta-blockers to other interventions were largely single, underpowered trials. Propranolol was comparable to other medications known to be effective including flunarizine, topiramate and valproate. For chronic migraine, propranolol was more likely to reduce headaches by at least 50% (RR: 2.0, 95% CI: 1.0-4.3). There was only one trial of beta-blockers for tension-type headache. CONCLUSIONS There is high quality evidence that propranolol is better than placebo for episodic migraine headache. Other comparisons were underpowered, rated as low-quality based on only including single trials, making definitive conclusions about comparative effectiveness impossible. There were few trials examining beta-blocker effectiveness for chronic migraine or tension-type headache though there was limited evidence of benefit. REGISTRATION Prospero (ID: CRD42017050335).
Collapse
Affiliation(s)
- Jeffrey L. Jackson
- Department of Medicine, Zablocki VA Medical Center, Milwaukee, WI, United States of America
| | - Akira Kuriyama
- Department of General Medicine, Kurashiki Central Hospital, Okayama, Japan
| | | | - Sarah Nickoloff
- Department of Medicine, Zablocki VA Medical Center, Milwaukee, WI, United States of America
| | - Derek Storch
- Department of Medicine, Zablocki VA Medical Center, Milwaukee, WI, United States of America
| | - Wilkins Jackson
- Department of Biology, University of Wisconsin-Milwaukee, Milwaukee, WI, United States of America
| | - Zhi-Jiang Zhang
- Department of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan, China
| | | |
Collapse
|
2
|
Jackson JL, Kay C, Scholcoff C, Nickoloff S, Fletcher K. Migraine prophylactic management in neurology and primary care (2006-2015). J Neurol 2018; 265:3019-21. [PMID: 30232610 DOI: 10.1007/s00415-018-9066-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2018] [Revised: 09/14/2018] [Accepted: 09/15/2018] [Indexed: 10/28/2022]
|
3
|
Soon YY, Siow HC, Tan CY. Assessment of Migraineurs Referred to a Specialist Headache Clinic in Singapore: Diagnosis, Treatment Strategies, Outcomes, Knowledge of Migraine Treatments And Satisfaction. Cephalalgia 2016; 25:1122-32. [PMID: 16305601 DOI: 10.1111/j.1468-2982.2005.00969.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
This study aimed to compare (i) migraineurs' diagnosis, treatment strategies and satisfaction when treated by community care physicians (CCPs) and at the specialist headache clinic; (ii) migraineurs' knowledge of migraine treatments and outcomes at baseline and at 3 months' interval. Thirty-eight patients were interviewed at baseline visit and 3 months after neurologist consultation, using a survey form which consisted of a series of self-designed questions, the MIDAS questionnaire and the SF-36 Health Survey. More patients were informed of the diagnosis of migraine by the neurologist than by CCPs. Compared with CCPs, the neurologist was more likely to employ preventive therapies, prescribe triptans and ask patients to keep a headache diary. Patients' number of days with headaches in the last 3 months, pain intensity, MIDAS score and five out of the eight SF-36 domain scores were significantly improved at the 3 months' interval ( P < 0.05) compared with baseline at the specialist headache clinic. More patients recognized migraine-specific therapies and reported satisfaction with treatment after the neurologist consultation. This is the first study detailing significant improvements in patients' clinical outcomes, knowledge of migraine treatments and satisfaction after consultation at a specialist headache clinic in Singapore.
Collapse
Affiliation(s)
- Y Y Soon
- Department of Pharmacy, Singapore General Hospital, Singapore
| | | | | |
Collapse
|
4
|
Jelinski SE, Becker WJ, Christie SN, Giammarco R, Mackie GF, Gawel MJ, Eloff AG, Magnusson JE. Clinical Features and Pharmacological Treatment of Migraine Patients Referred to Headache Specialists in Canada. Cephalalgia 2016; 26:578-88. [PMID: 16674767 DOI: 10.1111/j.1468-2982.2005.01077.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
We set out to examine selected clinical characteristics of migraine patients referred to neurologists specializing in headache in Canada, and to document their pharmacological therapy both before and after consultation with the neurologist. Demographic, clinical and pharmacotherapy data were collected at the time of consultation for 606 patients referred to five headache clinics and who were given a migraine diagnosis by the neurologist. Data were analysed as part of the Canadian Headache Outpatient Registry and Database (CHORD) Project. The mean age of the migraine patients was 39.7 years; and 82.5% were female. The majority of patients suffered severe impact from their headaches. Prior to consultation, 48.7% were taking a triptan; after consultation, 97.2% were on a triptan. Before consultation, 30.9% were on a prophylactic drug; after consultation, 70.4% were. 20.8% of patients were medication overusers. Of these medication overusers, 42.4% were overusing an opiate, usually in combination with other analgesics; 21.6% were overusing a triptan. Medication changes made by the neurologists at consultation included a large increase in the use of both triptans and prophylactic medications. Medication overuse, particularly opiate overuse, remains a significant problem in patients with migraine in Canada.
Collapse
Affiliation(s)
- S E Jelinski
- Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, and Richmond Hospital, British Columbia, Canada
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Affaitati G, Martelletti P, Lopopolo M, Tana C, Massimini F, Cipollone F, Lapenna D, Giamberardino MA, Costantini R. Use of Nonsteroidal Anti-Inflammatory Drugs for Symptomatic Treatment of Episodic Headache. Pain Pract 2016; 17:392-401. [PMID: 27207273 DOI: 10.1111/papr.12461] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2015] [Revised: 03/11/2016] [Accepted: 04/08/2016] [Indexed: 01/06/2023]
Abstract
INTRODUCTION Primary headaches have high epidemiologic impact but their symptomatic treatment often remains problematic. Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently used, but their modality of employment and efficacy/differential efficacy are highly variable. This study investigated current NSAID use for episodic headache at an Italian headache center (January 2000 to February 2013). METHODS A retrospective evaluation was performed on 6,443 patient records: migraine (n = 2,330), tension-type headache (TTH; n = 807), and migraine plus TTH (n = 3,306). RESULTS Among migraine patients, 80% had used NSAIDs in the past year. Preferences were: nimesulide (57%), ketoprofen (25%), and ibuprofen (24%); complete efficacy was significantly higher than incomplete/absent efficacy (P < 0.0001). NSAIDs were replaced with triptans in 53% of patients at first visit; after 1 year there was a spontaneous significant return to NSAIDs (56%; P < 0.0005). Among TTH patients, 90% were NSAID users; preferences were: nimesulide (48%), ketoprofen (47%), and diclofenac (19%), with significantly higher complete vs. incomplete/absent efficacy (nimesulide and ketoprofen, P < 0.02). Replacement with analgesics was performed in 24% of patients; after 1 year, there was a 29% return to NSAIDs. Among migraine plus TTH patients, 89% were NSAID users. Preferences were: nimesulide (44%), ibuprofen (42%), and ketoprofen (38%), with significantly higher complete vs. incomplete/absent efficacy (0.001 < P < 0.0001). Replacement with analgesics was performed in 31% of patients; after 1 year, there was a 37% return to NSAIDs. CONCLUSIONS Nonsteroidal anti-inflammatory drug use in headache was higher than could be hypothesized based on guidelines, with NSAID preferences not entirely coinciding with international recommendations. This outcome suggests the need for greater awareness of all treatment options in headache by both patients and physicians.
Collapse
Affiliation(s)
- Giannapia Affaitati
- Department of Medicine and Science of Aging, Headache Center, Geriatrics Clinic and Ce.S.I.-MeT, "G. D'Annunzio" University of Chieti, Chieti, Italy
| | - Paolo Martelletti
- Department of Clinical and Molecular Medicine, Regional Referral Headache Centre, "Sant'Andrea" Hospital, "Sapienza" University, Rome, Italy
| | - Mariangela Lopopolo
- Department of Medicine and Science of Aging, Headache Center, Geriatrics Clinic and Ce.S.I.-MeT, "G. D'Annunzio" University of Chieti, Chieti, Italy
| | - Claudio Tana
- Internal Medicine Unit, Guastalla Hospital, AUSL Reggio Emilia, Reggio Emilia, Italy
| | - Francesca Massimini
- Institute of Clinical Pathology, "G. D'Annunzio" University of Chieti, Chieti, Italy
| | - Francesco Cipollone
- Department of Medicine and Science of Aging, Headache Center, Geriatrics Clinic and Ce.S.I.-MeT, "G. D'Annunzio" University of Chieti, Chieti, Italy
| | - Domenico Lapenna
- Department of Medicine and Science of Aging, "G. D'Annunzio" University of Chieti, Chieti, Italy
| | - Maria Adele Giamberardino
- Department of Medicine and Science of Aging, Headache Center, Geriatrics Clinic and Ce.S.I.-MeT, "G. D'Annunzio" University of Chieti, Chieti, Italy
| | - Raffaele Costantini
- Institute of Surgical Pathology, "G. D'Annunzio" University of Chieti, Chieti, Italy
| |
Collapse
|
6
|
Vandelli D, Palazzoli F, Verri P, Rustichelli C, Marchesi F, Ferrari A, Baraldi C, Giuliani E, Licata M, Silingardi E. Development and validation of a liquid chromatography-tandem mass spectrometric assay for quantitative analyses of triptans in hair. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1017-1018:136-144. [PMID: 26970848 DOI: 10.1016/j.jchromb.2016.02.031] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Revised: 02/19/2016] [Accepted: 02/23/2016] [Indexed: 12/15/2022]
Abstract
Triptans are specific drugs widely used for acute treatment of migraine, being selective 5HT1B/1D receptor agonists. A proper assumption of triptans is very important for an effective treatment; nevertheless patients often underuse, misuse, overuse or use triptans inconsistently, i.e., not following the prescribed therapy. Drug analysis in hair can represent a powerful tool for monitoring the compliance of the patient to the therapy, since it can greatly increase the time-window of detection compared to analyses in biological fluids, such as plasma or urine. In the present study, a liquid chromatography-tandem mass spectrometric (LC-MS/MS) method has been developed and validated for the quantitative analysis in human hair of five triptans commonly prescribed in Italy: almotriptan (AL), eletriptan (EP), rizatriptan (RIZ), sumatriptan (SUM) and zolmitriptan (ZP). Hair samples were decontaminated and incubated overnight in diluted hydrochloric acid; the extracts were purified by mixed-mode SPE cartridges and analyzed by LC-MS/MS under gradient elution in positive multiple reaction monitoring (MRM) mode. The procedure was fully validated in terms of selectivity, linearity, limit of detection (LOD) and lower limit of quantitation (LLOQ), accuracy, precision, carry-over, recovery, matrix effect and dilution integrity. The method was linear in the range 10-1000pg/mg hair, with R(2) values of at least 0.990; the validated LLOQ values were in the range 5-7pg/mg hair. The method offered satisfactory precision (RSD <10%), accuracy (90-110%) and recovery (>85%) values. The validated procedure was applied on 147 authentic hair samples from subjects being treated in the Headache Centre of Modena University Hospital in order to verify the possibility of monitoring the corresponding hair levels for the taken triptans.
Collapse
Affiliation(s)
- Daniele Vandelli
- Department of Diagnostic Medicine, Clinical and Public Health, Unit of Legal Medicine-Forensic Toxicology Laboratory, University of Modena and Reggio Emilia, via del Pozzo, 71, 41124 Modena, Italy.
| | - Federica Palazzoli
- Department of Diagnostic Medicine, Clinical and Public Health, Unit of Legal Medicine-Forensic Toxicology Laboratory, University of Modena and Reggio Emilia, via del Pozzo, 71, 41124 Modena, Italy
| | - Patrizia Verri
- Department of Diagnostic Medicine, Clinical and Public Health, Unit of Legal Medicine-Forensic Toxicology Laboratory, University of Modena and Reggio Emilia, via del Pozzo, 71, 41124 Modena, Italy
| | - Cecilia Rustichelli
- Department of Life Sciences, University of Modena and Reggio Emilia, via G. Campi, 103, 41125 Modena, Italy
| | - Filippo Marchesi
- Department of Diagnostic Medicine, Clinical and Public Health, Unit of Legal Medicine-Forensic Toxicology Laboratory, University of Modena and Reggio Emilia, via del Pozzo, 71, 41124 Modena, Italy
| | - Anna Ferrari
- Department of Diagnostic, Clinical and Public Health Medicine, Unit of Medical Toxicology, Headache and Drug Abuse Centre, University of Modena and Reggio Emilia, via del Pozzo, 71, 41124 Modena, Italy
| | - Carlo Baraldi
- Department of Diagnostic, Clinical and Public Health Medicine, Unit of Medical Toxicology, Headache and Drug Abuse Centre, University of Modena and Reggio Emilia, via del Pozzo, 71, 41124 Modena, Italy
| | - Enrico Giuliani
- Clinical and Experimental Medicine Doctorate School, University of Modena and Reggio Emilia, via del Pozzo, 71, 41124 Modena, Italy
| | - Manuela Licata
- Department of Diagnostic Medicine, Clinical and Public Health, Unit of Legal Medicine-Forensic Toxicology Laboratory, University of Modena and Reggio Emilia, via del Pozzo, 71, 41124 Modena, Italy
| | - Enrico Silingardi
- Department of Diagnostic Medicine, Clinical and Public Health, Unit of Legal Medicine-Forensic Toxicology Laboratory, University of Modena and Reggio Emilia, via del Pozzo, 71, 41124 Modena, Italy
| |
Collapse
|
7
|
Kress HG, Baltov A, Basiński A, Berghea F, Castellsague J, Codreanu C, Copaciu E, Giamberardino MA, Hakl M, Hrazdira L, Kokavec M, Lejčko J, Nachtnebl L, Stančík R, Švec A, Tóth T, Vlaskovska MV, Woroń J. Acute pain: a multifaceted challenge - the role of nimesulide. Curr Med Res Opin 2016; 32:23-36. [PMID: 26414386 DOI: 10.1185/03007995.2015.1100986] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND This article summarizes the outcome from an international consensus meeting, which took place in Vienna on 4 November 2014. SCOPE The aim of the meeting was to provide the state of the art on the pathophysiology and treatment of acute pain with special emphasis on nimesulide, a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of acute pain and primary dysmenorrhea. Besides the data on the mechanisms of acute inflammatory pain and on the efficacy and safety of nimesulide in patients affected by different forms of acute pain, the clinical experience of attending experts was discussed based on selected case reports. RESULTS The members of this consensus group recognized that nimesulide is a NSAID highly effective in the treatment of several painful situations with an acute inflammatory component including primary dysmenorrhea. Although safety concerns regarding nimesulide have emerged in recent years, both robust new epidemiological data and clinical experience confirm a positive benefit/risk profile of nimesulide in the treatment of several forms of acute pain. CONCLUSIONS The members of this international consensus group concluded that nimesulide, when used appropriately, remains a particularly valuable and safe option for the treatment of several conditions characterized by the presence of acute inflammatory pain because of the rapid onset of the analgesic action, and the positive evidence-based benefit/risk profile.
Collapse
Affiliation(s)
- H G Kress
- a a Medical University/AKH Vienna - Dept. of Special Anaesthesia and Pain Therapy , Vienna , Austria
| | - A Baltov
- b b Emergency Trauma Hospital 'N.I. Pirogov' -Department of Trauma Surgery , Sofia , Bulgaria
| | - A Basiński
- c c Medical University of Gdańsk, Clinical Emergency Department of the University Clinical Center , Gdańsk , Poland
| | - F Berghea
- d d Clinical Hospital Saint Maria, Carol Davila University of Medicine, Department of Rheumatology , Bucharest , Romania
| | - J Castellsague
- e e RTI Health Solutions International , Barcelona , Spain
| | - C Codreanu
- f f Center of Rheumatic Disease 'Dr. Ion Stoia', Carol Davila University of Medicine, Rheumatology Department , Bucharest , Romania
| | - E Copaciu
- g g University Emergency Hospital, Carol Davila University of Medicine - Anesthesia and Intensive Care Department , Bucharest , Romania
| | - M A Giamberardino
- h h 'G. d'Annunzio' University of Chieti-Pescara - Department of Medicine and Science of Aging , Chieti , Italy
| | - M Hakl
- i i Masaryk University St. Ann's University Hospital - Department of Anesthesiology and Intensive Care Medicine , Brno , Czech Republic
| | - L Hrazdira
- j j Faculty of Sports Studies Masaryk University - Department of Health Support , Brno , Czech Republic
| | - M Kokavec
- k k Orthopedic Department, Children's Faculty Hospital , Bratislava , Slovak Republic
| | - J Lejčko
- l l University Hospital Pilsen - Department of Anaesthesiology and Intensive Care , Plzeň , Czech Republic
| | - L Nachtnebl
- m m Masaryk University St. Anne's University Hospital - 1st Orthopaedics Department , Brno , Czech Republic
| | - R Stančík
- n n Research Institute of Rheumatic Diseases in Piešťany -National Institute of Rheumatic Diseases , Piešťany , Slovak Republic
| | - A Švec
- o o University Hospital Bratislava - First Department of Orthopaedics and Trauma Surgery , Bratislava , Slovak Republic
| | - T Tóth
- p p MÁV PolyClinic - Department of Rheumatology , Debrecen , Hungary
| | - M V Vlaskovska
- q q Medical University of Sofia - Department of Pharmacology and Toxicology , Sofia , Bulgaria
| | - J Woroń
- r r Jagellonian University College of Medicine - Department of Clinical Pharmacology and Department of Pain Treatment and Palliative Care , Kraków , Poland
| |
Collapse
|
8
|
Pouchain E, Costa F, Bezerra T, Soares E. Comparative efficacy of nimesulide and ketoprofen on inflammatory events in third molar surgery: a split-mouth, prospective, randomized, double-blind study. Int J Oral Maxillofac Surg 2015; 44:876-84. [DOI: 10.1016/j.ijom.2014.10.026] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2014] [Revised: 09/30/2014] [Accepted: 10/22/2014] [Indexed: 11/20/2022]
|
9
|
Abstract
INTRODUCTION Chronic migraine is often complicated by medication-overuse headache (MOH), a headache due to excessive intake of acute medications. Chronic migraine and MOH are serious and disabling disorders. Since chronic migraine derives from the progression of originally episodic migraine, the fundamental therapeutic strategy is prevention. This narrative review describes how to try to prevent the development of MOH and how to manage it once it has appeared. AREAS COVERED A PubMed database search (from 1988 to January 2015) and a review of published studies on chronic migraine and MOH were conducted. EXPERT OPINION In spite of progress in migraine treatment, the prevalence of chronic headaches and MOH has not changed in the course of time. Today, a large number of migraine patients have turned to numerous expert physicians and experienced all sorts of prophylactic treatments without decisive benefits. Their condition seems to have crystallized even more as chronic and intractable. This means that to prevent chronification and MOH, we need more effective drugs and better strategies to use them. In particular, we must detect disease biomarkers and predictive factors for drug response that allow for personalized treatment when migraine is still episodic and make analgesic overuse pointless.
Collapse
Affiliation(s)
- Anna Ferrari
- University of Modena and Reggio Emilia, Headache and Drug Abuse Research Centre, Department of Diagnostic, Clinical and Public Health Medicine , Via del Pozzo, 71 - 41124 Modena , Italy +39 05 9422 4064 ; +39 05 9422 4069 ;
| | | | | |
Collapse
|
10
|
Jelinski SE, Becker WJ, Christie SN, Giammarco R, Mackie GF, Gawel MJ, Eloff AG, Magnusson JE. Demographics and Clinical Features of Patients Referred to Headache Specialists. Can J Neurol Sci 2014; 33:228-34. [PMID: 16736736 DOI: 10.1017/s0317167100005035] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
ABSTRACT:Objective:To examine demographic characteristics and clinical features of headache patients referred to neurologists specializing in headache in Canada.Methods:Demographic and clinical data were collected at the time of consultation for 865 new headache patients referred to five headache-specialty clinics in Canada. The Headache Impact Test (HIT-6) and Migraine Disability Questionnaire (MIDAS) were used to measure headache impact and disability. Data were analyzed as part of the Canadian Headache Outpatient Registry and Database (CHORD) Project.Results:The average age of the patients was 40 years and the majority were female (78%). Most were employed either full time (49%) or part time (13%). The majority of patients were diagnosed with either migraine or tension-type headache (78%). Over a third of patients experienced headache every day, and half had experienced a headache in the previous month which was of severe intensity. Most (80%) scored in the “very severe” category of the HIT-6 and over half (55%) were severely disabled as measured by the MIDAS.Conclusion:Patients referred to headache specialists in Canada are severely disabled by their headache disorders. These patients are in the most productive phase of their lives in terms of age and employment. It is important to provide the best available treatment to headache patients in order to minimize the disability and impact of their headache disorders.
Collapse
Affiliation(s)
- Susan E Jelinski
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Abstract
Aim: The aim of the study was to evaluate the pharmacological treatment of migraine patients by general practitioners before referral to a neurologist. First, was the pharmacological treatment in accordance with the Dutch College of General Practitioners headache guideline? Second, which migraine characteristics were associated with receiving migraine-specific medication? Methods: Migraine patients (age ≥18 years) who visited the neurology outpatient clinic for the first time were included. Migraine characteristics and pharmacological status were collected retrospectively for each patient from the general practitioner’s referral letter, hospital record and a headache characteristics questionnaire. Results: A total of 420 migraine patients were included. Only 18.3% of the patients with two or more migraine attacks per month were using prophylactic medication. Furthermore, only 11.7% of patients with symptoms of nausea and/or vomiting were using anti-emetic medication. More than half of patients (51.7%) were using triptans and were likely to have typical migraine symptoms and a long history of migraine. Conclusions: Migraine prophylactic medication and anti-emetics are underutilized in the primary care setting for migraine patients in the Netherlands, when compared to the general practitioners guideline. It is important to enhance the knowledge of general practitioners regarding the diagnosis of migraine, and to increase awareness of the headache guideline.
Collapse
Affiliation(s)
- R Zielman
- Department of Neurology, Leiden University Medical Center, the Netherlands
| | - PJL Veenstra
- Department of Neurology, Isala Clinics, the Netherlands
| | - EW van Zwet
- Department of Medical Statistics, Leiden University Medical Center, the Netherlands
| | | |
Collapse
|
12
|
Abstract
OBJECTIVE To investigate the factors involved in the delayed diagnosis of migraine without aura among patients attending a tertiary center for headache diagnosis and management. METHODS Two hundred consecutive patients were divided into 3 groups according to the time elapsed from the first clinical manifestations and the diagnosis of migraine at our center. RESULTS The interval was <1 year in 16.5% of patients (n = 33); from 1 to 5 years in 30% (n = 60); and >5 years in 53.5% (n = 107). Younger age at migraine onset and a lower level of education were significantly associated with a longer time to diagnosis (P = .01 and P = .0001, respectively). Longer delays were significantly associated with a larger number of specialists consulted (P < .05). CONCLUSION Our findings suggest an insufficient awareness of the diagnostic criteria of migraine by non-specialist physicians, who often prescribe expensive and unnecessary diagnostic investigations that do not alleviate patients' symptoms while wasting health care resources.
Collapse
Affiliation(s)
- Giovanna Viticchi
- Polytechnic University of Marche-Department of Neuroscience, Ancona, Italy
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
AIMS The aims of this survey were: (i) to examine the pharmacoepidemiology of triptans in a headache centre; (ii) to compare the characteristics of patients who continued to take triptans with those of patients who had discontinued them. METHODS We enrolled all migraine patients according to ICHD-II criteria, ensuring they were over 18 years of age, consecutively examined during a follow-up visit at the Headache Centre of the University Hospital of Modena from October 2008 to March 2009. Only patients who had used or were using a triptan were included. A specific questionnaire about the use and tolerability of triptans was created for the study and administered to every patient. RESULTS On the whole, 343 patients (migraine without aura: 72%; chronic migraine: 26%; migraine with aura: 2%; mean age 40.4 +/- 10 years) had used or were using triptans. Most patients (72%) continued to use triptans, above all for their efficacy. The minority (28%) discontinuing them were younger and suffered from less severe migraine; 59% of them had discontinued triptans because of adverse effects. Indeed, 92% of these patients versus 57% of patients who were currently using triptans reported adverse effects (p < .0001, Fisher's exact test). The number of patients reporting adverse effects significantly decreased with age (r = -0.230, p < .005, simple linear regression analysis). The triptan discontinued by the highest percentage of patients (84%) was subcutaneous 6 mg sumatriptan. Significantly more patients reported adverse effects with subcutaneous 6 mg (89%) and tablet 100 mg sumatriptan (67%) than with any other triptan. CONCLUSIONS The increase of the tolerability of triptans with age could partly explain why younger patients suffering from less severe migraine tend to discontinue triptans more than older patients suffering from more severe migraine. In the latter, the efficacy and better tolerability (but not necessarily safety) of triptans could foster the overuse of these medications.
Collapse
Affiliation(s)
- Anna Ferrari
- Headache and Drug Abuse Inter-Dep Research Centre,Division of Toxicology and Clinical Pharmacology, University of Modena and Reggio Emilia, Italy.
| | | | | |
Collapse
|
14
|
Panconesi A, Pavone E, Franchini M, Mennuti N, Bartolozzi M, Guidi L, Banfi R. Triptans: low utilization and high turnover in the general population. Cephalalgia 2010; 30:576-81. [PMID: 19732070 DOI: 10.1111/j.1468-2982.2009.02001.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Studies performed in selected populations have shown a poor utilization of triptans for migraine. Our study was aimed at establishing patterns of triptans utilization in a large community using the pharmaceutical prescriptions database of two consecutive years in a regional Health Authority in Italy. About 0.5% of the population observed received triptans prescriptions in a year, but > 50% of the cases received only one prescription. On the other hand, 46% of triptan users did not receive a triptan prescription in the following year (past users): in 80% of cases, patients received only 1-2 triptan packages. The evaluation of the discontinued triptan type has shown percentages varying between 30 and 70%. The percentage of triptan users who received a triptan prescription for the first time in the successive year of study (new users) was 52%. These findings together highlight a high turnover in triptans utilization. Less than 15% of subjects received more than one triptan product in the 2 years. In conclusion, we observed a low percentage of triptan users and a low rate of utilization, associated with a high percentage of discontinuation and new utilization (high turnover), without any substantial increase in triptans utilization during the years. All these data probably do not support optimal satisfaction with triptan therapy.
Collapse
Affiliation(s)
- A Panconesi
- Health Authority 11, Empoli, Florence, Italy.
| | | | | | | | | | | | | |
Collapse
|
15
|
Cevoli S, D'Amico D, Martelletti P, Valguarnera F, Bene ED, Simone RD, Sarchielli P, Narbone MC, Testa L, Genco S, Bussone G, Cortelli P. Underdiagnosis and Undertreatment of Migraine in Italy: A Survey of Patients Attending for The First Time 10 Headache Centres. Cephalalgia 2009; 29:1285-93. [DOI: 10.1111/j.1468-2982.2009.01874.x] [Citation(s) in RCA: 84] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
The aim of this study was to asses the clinical features, pattern of healthcare and drug utilization of migraine patients attending 10 Italian headache centres (HC). Migraine is underdiagnosed and undertreated everywhere throughout the world, despite its considerable burden. Migraine sufferers often deal with their problem alone using self-prescribing drugs, whereas triptans are used by a small proportion of patients. All patients attending for the first time 10 Italian HCs over a 3-month period were screened for migraine. Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine. Patient satisfaction with their usual therapy for the migraine attack was evaluated with the Migraine-Assessment of Current Therapy (ACT) questionnaire. The quality of life of migraine patients was assessed by mean of Short Form (SF)-12 and Migraine-Specific Quality of life (MSQ) version 2.1 questionnaires. Of the 2675 patients who attended HCs for the first time during the study period, 71% received a diagnosis of migraine and the first 953 subjects completed the study out of 1025 patients enrolled. Only 26.8% of migraine patients had a previous diagnosis of migraine; 62.4% of them visited their general practitioner (GP) in the last year, 38.2% saw a specialist for headache, 23% attended an Emergency Department and 4.5% were admitted to hospital for migraine; 82.8% of patients used non-specific drugs for migraine attacks, whereas 17.2% used triptans and only 4.8% used a preventive migraine medication. Triptans were used by 46.4% of patients with a previous diagnosis of migraine. About 80% of migraine patients took over-the-counter medications. The Migraine-ACT revealed that 60% of patients needed a change in their treatment of migraine attacks, 85% of whom took non-specific drugs. Both the MSQ version 2.1 and the SF-12 questionnaires indicated a poor quality of life of most patients. Migraine represents the prevalent headache diagnosis in Italian HCs. Migraine is still underdiagnosed in Italy and migraine patients receive a suboptimal medical approach in our country, despite the healthcare utilization of migraine subjects being noteworthy. A cooperative network involving GPs, neurologists and headache specialists is strongly desirable in order to improve long-term migraine management in Italy.
Collapse
Affiliation(s)
- S Cevoli
- Department of Neurological Sciences, Alma Mater Studiorum, Università di Bologna, Bologna
| | - D D'Amico
- Department of Neurological Sciences, Fondazione IRCCS Istituto Neurologico C. Besta, Milan
| | - P Martelletti
- Centro di Riferimento Regionale per le Cefalee, Dipartimento di Scienze Mediche, A.O. Sant'Andrea, Roma
| | - F Valguarnera
- Centro Cefalee, Ospedale Antero Micone, Sestri Ponente, Genova
| | - E Del Bene
- Centro Cefalee, Dipartimento di Medicina Interna, Villa Monna Tessa, Firenze
| | - R De Simone
- Centro Cefalee, Dipartimento di Scienze Neurologiche, Università Federico II, Napoli
| | - P Sarchielli
- Centro Cefalee Clinica Neurologica, Università degli Studi di Perugia, Perugia
| | - MC Narbone
- Department of Neurosciences—A.O.U. ‘G. Martino’—Contesse, Messina
| | - L Testa
- Centro Cefalee della Clinica Neurologica, Università del Piemonte Orientale A. Avogadro, A.O. Maggiore della Carità-Novara
| | - S Genco
- Clinica Neurologica, II Policlinico, Bari, Italy
| | - G Bussone
- Department of Neurological Sciences, Fondazione IRCCS Istituto Neurologico C. Besta, Milan
| | - P Cortelli
- Department of Neurological Sciences, Alma Mater Studiorum, Università di Bologna, Bologna
| |
Collapse
|
16
|
Cuvellier JC, Donnet A, Guégan-Massardier E, Nachit-Ouinekh F, Parain D, Vallée L. Treatment of primary headache in children: a multicenter hospital-based study in France. J Headache Pain 2009; 10:447-53. [PMID: 19771388 PMCID: PMC2778781 DOI: 10.1007/s10194-009-0158-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2009] [Accepted: 09/03/2009] [Indexed: 10/25/2022] Open
Abstract
The aim of this 6-month, prospective, multicenter study of 398 children and adolescents with primary headaches was to collect data on headache treatment in neuropediatric departments. Treatments were compared before and after consultation. Prior to consultation, the acute treatments that had been prescribed most frequently were paracetamol (82.2% of children) and non-steroidal anti-inflammatory drugs treatment (53.5%); 10.3% had received a prophylactic treatment. No differences in either acute or prophylactic treatment with respect to headache diagnosis were observed. After the neuropediatric consultation, paracetamol was replaced by a non-steroidal anti-inflammatory drug in about three-quarters of cases and by triptan in about one-quarter of cases. The number of children prescribed a prophylactic treatment nearly doubled, whereas there was a 5-fold and 23-fold increase in psychotherapy and relaxation training, respectively, between pre-referral and referral. We conclude that specific treatments were underused for primary headache.
Collapse
Affiliation(s)
- Jean-Christophe Cuvellier
- Division of Paediatric Neurology, Department of Paediatrics, Lille Faculty of Medicine and Children's Hospital, Lille, France.
| | | | | | | | | | | |
Collapse
|
17
|
Levrini L, Carraro M, Rizzo S, Salgarello S, Bertelli E, Pelliccioni GA, Garau V, Bandettini M, Caputi S, Lörincz A, Szûcs A. Prescriptions of NSAIDs to patients undergoing third molar surgery : an observational, prospective, multicentre survey. Clin Drug Investig 2009; 28:657-68. [PMID: 18783304 DOI: 10.2165/00044011-200828100-00006] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
BACKGROUND AND OBJECTIVES Surgical extraction of an impacted third molar is generally followed by acute post-operative pain that has been shown to be primarily inflammatory. Thus, use of NSAIDs in this context is appropriate and has been shown to be effective. Several drugs are employed for this purpose, but no information exists on the reasons why preference is given to one rather than another. The principal objective of this study was to evaluate the pattern of administration of NSAIDs in patients undergoing surgery for impacted third molar extraction. The study also aimed to collect information on the efficacy, onset and duration of the analgesic effect of routinely prescribed NSAIDs and to assess the duration of treatment with these drugs and their tolerability. METHODS This was an observational, multicentre, prospective survey. A total of 616 patients (38% male and 62% female) from the Italian Stomatology Clinics of the Universities of Bologna, Brescia, Cagliari, Chieti, Pavia, Pisa, Siena and Varese and from the Department of Oral and Maxillo-Facial Surgery of Semmelweis University, Budapest, were eligible for the study. Patients were evaluated over the 7 days following surgical extraction. NSAIDs were prescribed according to the normal prescribing habits of the centre and physician involved. The main outcomes of interest in the survey were the efficacy, onset and duration of analgesic effect, duration of therapy, and tolerability of the NSAIDs prescribed. RESULTS Nimesulide was the most prescribed NSAID (68%), followed by diclofenac, ketoprofen and ibuprofen. Because of the low proportion of patients receiving other NSAIDs, these patients were considered a single treatment group for evaluation purposes. Nimesulide, especially when given before patients started experiencing pain after surgery, was more effective than other NSAIDs in reducing the severity of pain on the day of surgery, in delaying the time to maximum intensity of pain, in providing complete pain relief and in prolonging the duration of analgesic effect on the day of surgery. These results are consistent with the known anti-inflammatory and analgesic actions of nimesulide and with the important role of inflammation in the onset of pain after this type of surgery. CONCLUSION These results confirm nimesulide as an effective reference drug for the treatment of post-operative dental pain and show that it has a positive benefit/risk profile in this setting.
Collapse
Affiliation(s)
- Luca Levrini
- Clinica Odontoiatrica, Università dell'Insubria, Varese, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Abstract
OBJECTIVE The Headache Management Pattern (HMP) programme was designed to evaluate the current clinical situation regarding the diagnosis, treatment and referral of headache in a European primary care setting. DESIGN AND METHODS A total of 705 GPs (from Germany, Portugal and Belgium), who regularly treated migraine patients, completed a questionnaire relating to four different case scenarios described in terms of symptoms, signs and medical history. Each GP completed clinical decision-trees which were created following IHS diagnostic criteria and published treatment guidelines. RESULTS Of those questioned, 90% accurately diagnosed a new migraine case and 54% prescribed early intervention with a triptan. However, 23.7% prescribed an NSAID, despite a past history of failed headache relief, and 7.2% indicated that they would refer their patients to a specialist. In the case of a patient whose migraine was deteriorating, 55% of GPs counselled early intervention with a triptan. For chronic migraine sufferers, 42.6% of GPs chose to refer them to a specialist, whilst about one-third made appropriate adjustments to the patient's treatment. The final case, tension-type headache, proved the most difficult scenario to assess, with only 26% of those questioned reaching an adequate diagnosis. Between-country differences in clinical practice may result from local reimbursement policy, treatment guidelines, and different healthcare systems/facilities (e.g., access to specialised care)--all of which could influence the results obtained. CONCLUSIONS A questionnaire such as the HMP programme inherently has limited depth, and the sampling procedure (GPs with triptan knowledge from three countries) needs to be considered when interpreting the results. Nevertheless, the survey provides important information relating to the management of headache in primary care, highlighting the need for both continuing medical education and also improved referral to specialist care.
Collapse
|
19
|
Panconesi A, Pavone E, Vacca F, Vaiani M, Banfi R. Triptans in the Italian population: a drug utilization study and a literature review. J Headache Pain 2008; 9:71-6. [PMID: 18317865 PMCID: PMC3476185 DOI: 10.1007/s10194-008-0020-3] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2007] [Accepted: 01/30/2008] [Indexed: 11/25/2022] Open
Abstract
Previous studies performed in selected populations show a poor utilization of triptans for migraine. The objectives of our study were to establish patterns of triptans utilization in a large sample, covering 1/10 of Italian population (5.57 millions), and to perform a review of published studies on this topic. We investigated drug prescription database collected during 2006 from 33 health authorities distributed in 8 different regions. About 0.6% of the subjects received at least one prescription of triptans in 1 year: 77.7% were females and 22.3% males. Age distribution shows that 9.5% of patients were aged above 65, and received prescriptions for 8.2% of packages. The review of the literature suggests that these percentages of utilization are common to several countries, and shows that occasional triptan users who received only one prescription in 1 year are a large percentage (40-60%); moreover, a minor population of triptan users utilize a large amount of total triptans. Finally triptans are frequently prescribed in people aged above 65 years, a population in which triptans are contraindicated or not recommended. Our study and the analyzed ones indicate suboptimal treatment of migraine patients with triptans and also an incorrect use in some patients (triptan abusers, elderly).
Collapse
|
20
|
Abstract
This contribution concerns the experience of chronic diseases and how it disrupts the trajectory of a person's biography, undermining his/her identity, self-reliance and social relationships. The study focuses particular attention on those diseases which have not yet been fully acknowledged and can, therefore, be considered a socially invisible disease: chronic headache is one of these. Thirty-one life stories were collected from patients attending a specialized headache centre in Northern Italy, and selected in order to include all common varieties of chronic headache. Following the principles of grounded theory, interviews began by adopting a minimal theoretical framework which consisted of asking people how they became aware of the objective (disease), subjective (illness) and social (sickness) aspects of their condition. The analysis highlighted particular points in the patients' life trajectories: first, the biographical disruption that takes place because of the disease; second, how people succeed or fail in identity negotiation, which is vital for developing an acceptable social representation of the disease. Results show that patient's choices follow a vicious circle, where a partial social representation of the disease is produced. People who suffer from chronic headache face a dilemma in social relationships: should they conceal their disease, or make it evident? If they conceal, any possible social representation of the disease is denied, which could lead to carrying the burden of the disease alone, with no social support. On the other hand, making chronic headache visible could result in stigma.
Collapse
Affiliation(s)
- Cristina Lonardi
- Department of Education, University of Verona, lungadige porta vittoria 17, 37129 Verona, Italy.
| |
Collapse
|
21
|
|
22
|
Abstract
The aim was to characterize the individual and socio-economic impact of headache in a patient population from The Danish Headache Centre. This was a cross-sectional study using a structured interview, prospective headache diaries and standardized self-administered questionnaires using the ICHD-II criteria. Fifty-five subjects (12 male and 43 female) with a median age of 41 years and a median headache frequency of 15 days/month participated. Very high utilization of the healthcare system and a high absence rate due to headache of 12 days/year were reported. Eighty-one percent experienced a marked decrease in work effectiveness. Overall, 91% felt hampered by their headache on a daily basis and 98% had had expenses for headache medication. Frequent headache disorders are highly costly, especially due to indirect costs. Prevention, early intervention or effective treatment strategies for headache disorders may therefore be highly cost effective, not only for the individual but also for society.
Collapse
Affiliation(s)
- G R Vinding
- Danish Headache Centre, Department of Neurology, University of Copenhagen, Glostrup Hospital, Glostrup, Denmark.
| | | | | | | | | |
Collapse
|
23
|
|
24
|
Odaguchi H, Wakasugi A, Ito H, Shoda H, Gono Y, Sakai F, Hanawa T. The efficacy of goshuyuto, a typical Kampo (Japanese herbal medicine) formula, in preventing episodes of headache. Curr Med Res Opin 2006; 22:1587-97. [PMID: 16870083 DOI: 10.1185/030079906x112769] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE The purpose of this clinical trial was to assess the efficacy of goshuyuto, a typical Kampo formula, in preventing episodes of headache in chronic headache patients. RESEARCH DESIGN AND METHODS Because the treatment target of a Kampo formula is decided on a basis different to that of Western medicine, we first selected patients belonging to a subgroup that responded to goshuyuto before conducting the usual randomized controlled trial. During stage 1, the subjects were instructed to orally consume goshuyuto for 4 weeks. Only those subjects judged as responders advanced to stage 2, during which a double-blind, randomized, placebo-controlled study was conducted. The subjects consumed the same dose of goshuyuto or placebo for 12 weeks. RESULTS Of the 91 subjects enrolled in stage 1, 60 were judged as responders. Of these, 53 advanced to stage 2; 28 were assigned to the goshuyuto group and 25 to the placebo group. The decrease in the number of days on which headache episodes occurred was greater in the goshuyuto group than in the placebo group (2.6 +/- 3.7 vs. 0.3 +/- 4.0 days, p = 0.034); no difference was observed with regard to the reduction in the frequency of consuming reliever medications (2.2 +/- 4.0 vs. 1.4 +/- 8.2, p = 0.672). Improvement in the associated symptoms was observed in more than 50% of the subjects in the goshuyuto group. CONCLUSION Goshuyuto is useful in preventing episodes of headache in chronic headache patients. Responder-limited design is a candidate for evaluating Kampo medicine.
Collapse
Affiliation(s)
- Hiroshi Odaguchi
- Department of Oriental Medicine, Doctoral Program of Medical Science, Kitasato University Graduate School, Sagamihara, Japan.
| | | | | | | | | | | | | |
Collapse
|
25
|
Abstract
AIM To develop and evaluate the clinimetric properties of a new migraine screening questionnaire: the Migraine Screen Questionnaire (MS-Q). BACKGROUND Migraine is a public health problem requiring screening programs and tools to ensure early detection. METHODS A questionnaire was developed based on the criteria of the International Headache Society (IHS) and a review of the literature by a committee of experts. Stage I: The original version of the MS-Q was distributed by mail and completed by Pfizer employees and self-administered to neurological patients; all subjects were afterward evaluated by a neurologist who was blinded to the MS-Q results, to establish an independent IHS diagnosis. Stage II: A final version of the MS-Q was administered to neurological patients to confirm clinimetric properties. Logistic regression and receiver-operator characteristic curve statistical methods were used and the 95% confidence interval, sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values, were estimated. RESULTS Of the 605 subjects recruited, 465 were evaluable (325 in stage I and 140 in stage II). Of the original 15 items, 5 conformed the final version of the MS-Q: frequency and intensity of headache; a duration of between 4 hours and 3 days; nausea; sensitivity to light/noise; and disability. A cutoff point of > or = 4 points showed a sensitivity of 0.93 (95% CI = 0.87 to 0.99), specificity of 0.81 (95% CI = 0.72 to 0.91), PPV of 0.83 (95% CI = 0.75 to 0.91), and NPV of 0.92 (95% CI = 0.85 to 0.99). Cronbach's alpha coefficient = 0.82. CONCLUSIONS The MS-Q showed adequate validity and reliability, and it could be a good screening tool for application to clinical practice and research.
Collapse
Affiliation(s)
- Miguel J A Láinez
- Hospital Clínico Universitario, Universidad de Valencia, Neurology Department, Spain
| | | | | | | | | | | | | |
Collapse
|
26
|
Cerbo R, Centonze V, Grazioli I, Tavolato B, Trenti T, Uslenghi C, Sternieri E. Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine in the treatment of episodic tension-type headache: a double-blind, randomized, nimesulide-controlled, parallel group, multicentre trial. Eur J Neurol 2005; 12:759-67. [PMID: 16190913 DOI: 10.1111/j.1468-1331.2005.01056.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
In this double-blind, randomized, parallel group, multicentre study the efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine (IndoProCaf) and nimesulide were compared over an 8-h period in the treatment of two consecutive episodes of tension-type headache (TTH). Both drugs were administered orally. Of 54 randomized patients, 40 were compliant to the protocol. More patients on IndoProCaf than on nimesulide were pain-free at 2 h post-dose (45% vs. 10%; P<0.05), reached a pain reduction of at least 50% at 2 (75% vs. 30%; P<0.05) and 4 h post-dose (90% vs. 58%; P<0.05), and had a statistically significant lower mean time to a 50 and 100% pain reduction in the second TTH episode. A higher percentage of patients reached a 50 or 100% pain reduction at 2 h post-dose with IndoProCaf compared with nimesulide, in two of two treated TTH episodes. A clinically and statistically significant change within each treatment group over time was found for the severity of pain, the headache intensity difference (HID), the sum of headache intensity difference (SHID), the maximum headache intensity difference (MAXHID), the headache relief (HER), the sum of total headache relief (TOTHER) and the maximum headache relief (MAXHER). In conclusion, IndoProCaf showed to be superior, but globally not statistically different from nimesulide in the treatment of episodic TTH. Both drugs were very effective and well tolerated.
Collapse
Affiliation(s)
- R Cerbo
- Department of Neurological Sciences, University La Sapienza, Rome, Italy
| | | | | | | | | | | | | |
Collapse
|
27
|
Ferrari A, Ottani A, Bertolini A, Cicero AFG, Coccia CPR, Leone S, Sternieri E. Adverse reactions related to drugs for headache treatment: clinical impact. Eur J Clin Pharmacol 2005; 60:893-900. [PMID: 15657778 DOI: 10.1007/s00228-004-0864-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2004] [Accepted: 10/25/2004] [Indexed: 11/29/2022]
Abstract
OBJECTIVE To assess the clinical impact of adverse reactions related to drugs for primary headache treatment. METHODS We examined the adverse reactions to 360 medications prescribed by the specialists of the Headache Centre of the University of Modena and Reggio Emilia to 256 consecutive outpatients (214 female, 42 male; mean age: 38.88 +/- 14.06 years; range 10-72 years). Adverse reactions were reported by patients during scheduled follow-up visits, classified by specialists and reassessed by a clinical pharmacologist. RESULTS Adverse reactions with a causal relationship classified as definite/probable/possible were 202 (56%): 62% (80/129) were due to acute treatments and 53% (122/231) to prophylactic treatments (chi2 test, P = 0.115 ns). More than 90% of the adverse reactions were of limited intensity [mild (58%) or moderate (36%)]. Only 5% were severe, and two reactions (1%) were serious. The most affected apparatus was the nervous system (41%). Of these adverse reactions, 43% caused the discontinuance of the treatment, especially of prophylaxis (54%). Patients evaluated 70% of the medications as effective, but, at the same time, they considered most of the adverse reactions (69%) unacceptable. CONCLUSION Adverse reactions related to headache medications have a strong impact on patients' management, even if their real intensity and severity are usually very limited. Drugs for headache treatment are still far from being ideal drugs. To prevent the discontinuance of effective medications, the physician, prior to prescribing, should assess, together with the patient, the acceptability of the more common adverse drug reactions.
Collapse
Affiliation(s)
- Anna Ferrari
- Division of Toxicology and Clinical Pharmacology, Headache Centre, University of Modena and Reggio Emilia, Policlinico, Largo del Pozzo, 71-41100 Modena, Italy.
| | | | | | | | | | | | | |
Collapse
|